Xcout Intel
Amplyx Pharmaceuticals, Inc. competitors & alternatives
The 12 closest competitors and alternatives to Amplyx Pharmaceuticals, Inc. among biopharma companies — ranked by similarity to what Amplyx Pharmaceuticals, Inc. actually does, not by market-cap band.
Subscribe to see Amplyx Pharmaceuticals, Inc.’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
About Amplyx Pharmaceuticals, Inc.
Amplyx Pharmaceuticals, Inc. was a San Diego-based clinical-stage biotechnology company developing treatments for serious and potentially life-threatening fungal infections. Its lead investigational drug, fosmanogepix, was acquired by Pfizer when Pfizer acquired Amplyx in 2021 and is being developed for patients with invasive fungal diseases.
Amplyx Pharmaceuticals, Inc. at a glance
Amplyx Pharmaceuticals, Inc. is a biopharma company headquartered in United States. Its most recent funding round raised $81.5M in April 2021.
Amplyx Pharmaceuticals, Inc. funding rounds
The 4 most recent:
| Date | Round | Amount | Investors |
|---|---|---|---|
| — | $81.5M | 13 named | |
| SEC Form D filing | $91.3M | — | |
| Series C | $91.3M | 12 named | |
| SEC Form D filing | $23.7M | — |
Who invested in each round, lead investors, valuations and the co-investor graph — open the full funding history →
Top 12 Amplyx Pharmaceuticals, Inc. competitors
Ranked by semantic similarity — how close each company is to Amplyx Pharmaceuticals, Inc. by what it does, using Xcout's live company graph. Click any company for its full profile, or its competitor set.
Drug Discovery
Pulmocide is a UK drug-discovery and development company focused on inhaled treatments for serious fungal lung infections. Its lead candidate, opelconazole (PC945), is an inhaled antifungal being developed for pulmonary aspergillosis and related respiratory fungal diseases, serving patients with difficult-to-treat pulmonary infections.
Drug Discovery
Pieris Pharmaceuticals, Inc. is a clinical-stage biotechnology company headquartered in Boston, Massachusetts. The company discovers and develops Anticalin-based drugs designed to address significant medical needs.
Drug Discovery
Founded in 2021 and headquartered in Shenzhen, China, MagicRNA Biotechnology Co., Ltd. is a clinical-stage biotechnology company focused on nucleic acid drug delivery and the research and development of next-generation mRNA and lipid nanoparticle technologies for the treatment of cancer and infectious diseases.
Drug Discovery
OncoMyx Therapeutics, Inc. is a biotechnology company headquartered in Phoenix, Arizona, that develops innovative oncolytic immunotherapies to target and destroy tumors.
Drug Discovery
Omniox, Inc. is an early-stage biopharmaceutical company located in San Francisco, California, focused on developing new medicines for hypoxic diseases.
Drug Discovery
Smartbax is a biotechnology startup founded in Munich, Germany, in 2021, dedicated to developing innovative next-generation antibiotics to combat the rising threat of multidrug-resistant bacteria.
Drug Discovery
Tacalyx is a life sciences and biotechnology company headquartered in Berlin, Germany, focused on developing lead TACA-targeted therapeutics.
Biopharmaceuticals
Cidara Therapeutics, Inc. is a biotechnology company focused on developing late-phase antiviral and immunotherapy agents, with operations based in San Diego, California and Rahway, New Jersey.
Biopharmaceutical
F2G is a biotechnology research company headquartered in the UK with subsidiaries in the US and Austria. The company specializes in developing novel therapeutics and antifungal treatments for rare fungal infections.
Biopharmaceuticals
Achaogen Inc was a biopharmaceutical company headquartered in South San Francisco, California. The company focused on discovering, developing, and commercializing novel antibacterial treatments.
Biopharmaceuticals
Arena Pharmaceuticals, Inc. was a biopharmaceutical company that discovered and developed medicines for cardiovascular, gastrointestinal, and central nervous system diseases. It was acquired by Pfizer in 2022, primarily for its investigational inflammatory disease drug etrasimod (now Velsipity).
Biopharmaceuticals
IDRx, Inc. is a clinical-stage biotechnology company headquartered in Plymouth, Massachusetts (with additional corporate office presence in New York). Founded in 2021, the company focuses on developing precision therapeutics and has entered an acquisition agreement with GSK.
Analyze another company
Search any company we track to see its competitive set.
Or describe a company
Paste a short paragraph describing a company or product — we'll find the most similar companies we track, scored 1–100.
See the full profile of Amplyx Pharmaceuticals, Inc. and its market
Funding, investors, tech stack, hiring signals, leadership and corporate events — for Amplyx Pharmaceuticals, Inc.and every competitor above — in one live dashboard.
Subscribe to Xcout Intel →